Abstract
摘要
相似文献
1
[Iron chelators].[铁螯合剂]
Med Clin (Barc). 1994 May 21;102(19):739-41.
2
Iron chelating in thalassaemia with left ventricular dysfunction.地中海贫血合并左心室功能障碍时的铁螯合作用
Heart. 2006 Oct;92(10):1440. doi: 10.1136/hrt.2006.088377.
3
Thalassaemia major: the murky story of deferiprone.重型地中海贫血：去铁酮的隐晦故事。
BMJ. 2004 Feb 14;328(7436):358-9. doi: 10.1136/bmj.328.7436.358.
4
A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.一种用于评估和改善地中海贫血患者去铁胺铁螯合治疗依从性的简单模型。
Ann N Y Acad Sci. 2005;1054:486-91. doi: 10.1196/annals.1345.065.
5
Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.对皮下注射依从性差的重度铁过载重型β地中海贫血患儿进行间歇性静脉注射去铁胺大剂量治疗的研究。
Pediatr Hematol Oncol. 2004 Jul-Aug;21(5):453-60. doi: 10.1080/08880010490457259.
6
Deferasirox Novartis.诺华公司的地拉罗司
Curr Opin Investig Drugs. 2005 Mar;6(3):327-35.
7
[Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].[两种用于铁螯合剂分析的含铁血黄素沉着症模型的比较评估]
Biull Eksp Biol Med. 1996 Sep;122(9):359-60.
8
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
Br J Haematol. 2007 Aug;138(3):374-81. doi: 10.1111/j.1365-2141.2007.06651.x.
9
Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.1,2 - 二乙基 - 3 - 羟基吡啶 - 4 - 酮、CP94及相关化合物的临床前和临床研究经验教训。
Adv Exp Med Biol. 1994;356:361-70. doi: 10.1007/978-1-4615-2554-7_38.
10
Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.重型β地中海贫血输血周期中的非转铁蛋白结合铁
Ann N Y Acad Sci. 2005;1054:429-32. doi: 10.1196/annals.1345.074.
Zotero 插件